Discussion with Scientist Pekka Puolasmaa and Project Manager Tuomas Nikula. The goal of gene therapy is to treat or cure severe diseases by carrying genetic material to the target cells to repair the incorrect or …
To display how Finland and Finnish solutions participate in the fight against cancer, Business Finland has compiled a new digital booklet, providing an overview of the extensive know-how and current areas of innovation. Biovian’s CDMO …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
The article compares the manufacture of viral vectors with that of recombinant proteins and reveals how Biovian has developed a solution to address the continuing challenges in gene therapy production. “Biovian has well over a …
Take Advantage of One-on-One Partnering! Schedule a virtual meeting with Magnus Gustafsson, the Head of Global Business Development of Biovian and find out how we can help your gene therapy or biopharma project from the …
Biovian is delighted to announce that Dr. Magnus Gustafsson has been appointed Head of Global Business Development. “We are very pleased that Magnus Gustafsson will assume the role of Head of Global Business Development at …
In this video the CEO of Biovian, Knut Ringbom, presents an overview of the year 2020, especially discussing the latest developments in the company. “Over the last year, we have experienced a lot of positive …
The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …
Biovian’s One-Stop-Shop service concept is presented in Biopharma Dealmakers’ July edition: “Biovian: a true One-Stop-Shop CDMO with gene therapy capacity and Nordic ethos” The article describes how the Nordic Biovian delivers a comprehensive and reliable …
